Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPA-15406 (Difamilast) in Atopic Dermatitis
NCT02914548Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of difamilast in atopic dermatitis (AD) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Responder Rate of Investigator's Global Assessment (IGA) of Disease Severity at 4 weeks. Started Sep 2016; status: completed.
02
Drugs
difamilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02914548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914548.